CJC-1295 (no DAC) / Modified GRF 1-29 Testing
MW: 3367.93 g/molHalf-life: ~30 minutes
GHRH analog without DAC, shorter half-life than CJC-1295 with DAC.
Mechanism of action
GHRH analog identical to Modified GRF 1-29. Short half-life produces pulsatile GH release similar to endogenous pattern. Often paired with ipamorelin.
Research areas
- ●Pulsatile GH stimulation research
- ●Combined with GHRPs
What we test on CJC-1295 (no DAC) / Modified GRF 1-29
Intact mass distinguishes from DAC version; RP-HPLC for purity.
Standard GH Secretagogues Panel
- ✓RP-HPLC purity
- ✓ESI-MS identity
- ✓Amino acid analysis
- ✓Residual solvents (GC-MS)
Common impurities & failure modes
- DAC-substituted product
If your 'no DAC' vial mass-specs at ~3647 Da instead of ~3368 Da, it is actually CJC-1295 with DAC.
- Asn deamidation
Stability-indicating.
- Truncation
Standard SPPS failures.
Related GH Secretagogues peptides
CJC-1295 (DAC)
3647.28 g/mol
GHRH analog with Drug Affinity Complex for extended half-life (~8 days).
GHRP-2
817.97 g/mol
Synthetic hexapeptide stimulator of GH release.
GHRP-6
872.97 g/mol
Hexapeptide stimulating GH secretion via the ghrelin receptor.
Hexarelin
887.04 g/mol
Potent hexapeptide GH secretagogue; also studied for cardiac effects.
Ibutamoren (MK-677)
528.66 g/mol
Orally active non-peptide GH secretagogue / ghrelin agonist.
Ipamorelin
711.86 g/mol
Selective pentapeptide GHRP. Minimal cortisol/prolactin release.